Study guide

18.1 Pharmacology Foundations: Classification, Pharmacokinetics & Pharmacodynamics

COPR Primary Care Paramedic PCP

Track your progress as you read

Finished sections get a check mark.

1 Introduction: The COPR PCP Exam & How to Use This Guide

0.1 About the COPR PCP Entry-to-Practice Examination 0.2 The 2024 CPCF Blueprint: Competence Areas, Weights & Question Targets 0.3 Eligibility, Attempts, Accommodations & a 12-Week Study Plan

2 Chapter 1: Professionalism, Ethics & Legal Framework

1.1 Ethical Practice, Professionalism & Values in Canadian Paramedicine 1.2 Professional Accountability, Candour & Duty to Report 1.3 Regulatory Framework, Scope of Practice & Informed Consent

3 Chapter 2: Patient-Centred Communication & Clinical Documentation

2.1 Therapeutic Communication, Empathy & De-escalation 2.2 Patient-Centred Interviewing & Comprehensive History Gathering 2.3 Clinical Information Sharing, Consent & Incident Disclosure 2.4 Clinical Documentation, Electronic Health Records & Privacy 2.5 Shared Decision-Making, Health Literacy & Engaging Patients in Care Plans

4 Chapter 3: Interprofessional Collaboration & Continuum of Care

3.1 Care Team Roles, Task Delegation & Shared Decision-Making 3.2 Scene Collaboration, Interagency Conflict & Safety Culture 3.3 Safe Transfer of Care, Clinical Handover & Transition Plans

5 Chapter 4: Evidence-Informed Practice & Continuing Competence

4.1 Clinical Mentorship, Role Modelling & Reflective Debriefing 4.2 Evidence-Informed Practice, Guideline Translation & Lifelong Learning 4.3 Continuing Competence, Personal Learning Plans & Adapting to a Changing Profession

6 Chapter 5: Professional Health, Safety & Operational Resilience

5.1 Paramedic Wellness, Occupational Stress Injuries & PTSI Recognition 5.2 Fitness for Duty, Ergonomics, Safe Lifting & Peer Support Systems 5.3 Monitoring Personal Health, Healthy Coping & Removing Yourself from Practice

7 Chapter 6: Health Advocacy, Equity & Culturally Safe Care

6.1 Social Determinants of Health, Cultural Safety & Anti-Oppressive Practice 6.2 Anti-Indigenous Racism, Truth and Reconciliation & Trauma-Informed Care 6.3 System-Level Advocacy, Social Accountability & Working Toward Reconciliation

8 Chapter 7: Situational Leadership & Scene Operations

7.1 Prehospital Scene Assessment, Initial Incident Command & Hazard Mitigation 7.2 Clinical Resource Coordination & Practice Improvement Systems

9 Chapter 8: Infection Prevention, Diagnostics & Scene Preparedness

8.1 Infection Prevention and Control: Routine Practices, PPE & Sharps Safety 8.2 Point-of-Care Risk Assessment & Mass Casualty/CBRNE Principles 8.3 Paramedic Scope along the Continuum & Diagnostic Laboratory Correlation 8.4 Point-of-Care Risk Assessment, Situational Awareness & Securing Additional Resources

10 Chapter 9: Patient Assessment, Physical Examination & Vital Signs

9.1 Primary Survey, Rapid Trauma/Medical Exam & Threat Identification 9.2 Secondary Assessment, History Integration (SAMPLE/OPQRST) & Lifespan Adaptation 9.3 Vital Signs Interpretation, Glasgow Coma Scale & Clinical Reassessment

11 Chapter 10: Diagnostic Monitoring: ECG & Capnography

10.1 Prehospital Pulse Oximetry, Glucometry & Urinalysis 10.2 Prehospital Electrocardiography: 3-Lead Monitoring & 12-Lead Acquisition 10.3 Continuous Waveform Capnography (EtCO2) & Ventilation Dynamics

12 Chapter 11: Airway Management & Ventilation Therapeutics

11.1 Basic Airway Maneuvers, Positioning, OPA/NPA & Suctioning Techniques 11.2 Supraglottic Airway (SGA) Devices & Tracheostomy Management 11.3 Oxygen Delivery Modalities, Regulators & Safety 11.4 Positive Pressure Ventilation, BVM Mechanics, PEEP & CPAP 11.5 Foreign Body Airway Obstruction: Recognition & Relief Across the Lifespan 11.6 Beyond CPAP: BiPAP, High-Flow Nasal Cannula Therapy & Choosing a Ventilation Strategy

13 Chapter 12: Cardiovascular Emergencies & Resuscitative Care

12.1 High-Performance Cardiopulmonary Resuscitation (CPR) & Automated/Manual Defibrillation 12.2 Acute Coronary Syndromes (ACS), STEMI Recognition & Pathophysiology 12.3 Heart Failure, Cardiogenic Shock & Left Ventricular Assist Devices (LVAD) 12.4 Cardiovascular Pharmacotherapy: Nitroglycerin, ASA & Epinephrine

14 Chapter 13: Trauma Emergencies, Hemorrhage Control & SMR

13.1 External Hemorrhage Control: Tourniquets, Wound Packing & Pelvic Binders 13.2 Spinal Motion Restriction (SMR) & Canadian C-Spine Rule Application 13.3 Thoracic & Abdominal Trauma Management 13.4 Musculoskeletal Trauma, Fractures, Splinting & Dislocation Reduction 13.5 Head Injury & Traumatic Brain Injury: Preventing Secondary Brain Injury 13.6 Burns and Soft-Tissue Injury: Thermal, Chemical, Electrical & Inhalation

15 Chapter 14: Medical, Endocrine, Toxicological & Environmental Emergencies

14.1 Acute Respiratory Distress: Asthma, COPD, Pulmonary Edema & Anaphylaxis 14.2 Neurological Emergencies: Stroke Syndromes, TIA, Seizures & Status Epilepticus 14.3 Endocrine Emergencies: Hypoglycemia, DKA/HHS & Glucagon/Dextrose Administration 14.4 Toxicological Emergencies, Opioid Toxicity, Naloxone & Environmental Exposure 14.5 Abdominal, Gastrointestinal & Hepatobiliary Emergencies 14.6 Genitourinary, Renal & Dialysis Emergencies 14.7 Haematologic, Immunologic, EENT & Dental Emergencies

16 Chapter 15: Special Populations: Obstetrics & Neonatal Resuscitation

15.1 Antepartum Emergencies, Preeclampsia & Normal Spontaneous Childbirth 15.2 Complicated Deliveries: Breech, Prolapsed Cord, Nuchal Cord & Postpartum Hemorrhage 15.3 Neonatal Resuscitation Program (NRP) in the Prehospital Setting

17 Chapter 16: Special Populations: Pediatrics, Geriatrics, Palliative & Vulnerable Patients

16.1 Pediatric Assessment Triangle (PAT), Common Emergencies & Pediatric Dosing 16.2 Geriatric Syndromes, Polypharmacy, Elder Vulnerability & Falls 16.3 Palliative Emergencies, Medical Assistance in Dying (MAID) & Community Paramedicine 16.4 Bariatric Patients, Limited Mobility & Patients With Different Abilities

18 Chapter 17: Clinical Foundations — Terminology, Anatomy, Physiology & Pathophysiology

17.1 Medical & Paramedic Terminology, Abbreviations and Anatomical Reference 17.2 Applied Anatomy & Physiology Across Body Systems and the Lifespan 17.3 Core Pathophysiology: Cellular Injury, Hypoperfusion & the Shock States

19 Chapter 18: Pharmacology & Safe Medication Administration

18.1 Pharmacology Foundations: Classification, Pharmacokinetics & Pharmacodynamics 18.2 Safe Medication Administration: The Rights, Dose Calculation & Error Management 18.3 Medication Routes: Enteral, Parenteral, Inhaled & Topical Administration

20 Chapter 19: Vascular Access, Fluid Therapy, Routine Care & Patient Movement

19.1 Peripheral IV Cannulation, Venipuncture, Saline Locks & Maintaining Infusions 19.2 Intraosseous Access, Crystalloid Fluid Therapy, Pressure Infusers & Blood Products 19.3 Routine Care: Urinary Catheters, Ostomy & Drainage Systems, Chest Tubes & Wound Care 19.4 Patient Handling, Movement, Positioning & Transfer to a Higher Level of Care

21 Chapter 20: Mental Health, Behavioural Emergencies & Substance Use

20.1 Mental Status Assessment, Cognition & Capacity to Consent 20.2 Behavioural Emergencies, Severe Agitation & Safe Restraint 20.3 Substance Use, Addictions, Withdrawal & Harm Reduction

18.1 Pharmacology Foundations: Classification, Pharmacokinetics & Pharmacodynamics

Key Takeaways Explain This Topic AI

Only the unbound fraction of a protein-bound drug is active, so hypoalbuminaemia in liver disease or critical illness increases the effect of a standard dose.

Sublingual, buccal, rectal, inhaled, and parenteral routes bypass first-pass hepatic metabolism, which is why swallowed nitroglycerin is ineffective.

Perfusion at the administration site is the dominant prehospital absorption factor, so subcutaneous and intramuscular absorption is slow and unpredictable in shock.

Naloxone is a competitive antagonist with a half-life of roughly 30 to 90 minutes, shorter than many opioids, which is the mechanism of renarcotization.

An intolerance is not an allergy — recording nausea from morphine as an allergy can deny a patient appropriate analgesia for life.

Last updated: September 2026

18.1 Pharmacology Foundations: Classification, Pharmacokinetics & Pharmacodynamics

CPCF Appendix A foundational knowledge #5 is one of the largest single items in the framework. It requires the Primary Care Paramedic to understand the paramedic's role in medication therapy, medication sources and drug classifications, naming conventions, mechanisms of entry and elimination, factors affecting absorption and distribution, dosage calculation, drug interactions, indications and contraindications, side effects, reference data, overdose recognition, the rights of administration, routes and injection sites, patient and supply preparation, and the procedures that follow a medication error.

This section covers the science. Section 18.2 covers safe administration and calculation, and Section 18.3 covers the routes named in skill #32.

The Paramedic's Role in Medication Therapy

A PCP administers medication under a medical directive or delegated authority , within the regulator-defined scope of practice for the designation (indicator A3.2 and competency H1), and within their own competence . Three implications are examinable:

Knowing a drug does not authorize giving it. Scope, authorization, and personal competence are independent gates (Section 4.3).

The paramedic administering is accountable for the decision and the act (indicator A2.3), even when the order came from someone else. "I was told to" is not a defence for administering a drug with an obvious contraindication.

Indicator H3.2 requires you to apply knowledge of the indications, contraindications, methods, and potential complications of every therapy you use. If you cannot state all four for a drug, you are not ready to give it.

Drug Names and Sources

  • Name type What it is Example
  • Chemical The molecular description 2-(acetyloxy)benzoic acid
  • Generic (non-proprietary) The official name, used internationally acetylsalicylic acid
  • Trade (proprietary, brand) The manufacturer's name Aspirin
  • Official The name in the official pharmacopoeia Acetylsalicylic Acid

Always communicate in generic names. Trade names vary between manufacturers and between countries, and a single generic drug may have a dozen brand names. Patients, however, know their medications by brand — so take the history in whatever name they use and convert it for the record and the handover.

Sources: plant (digoxin, atropine, morphine), animal (some insulins historically), mineral (magnesium sulfate), synthetic (most modern agents), and biotechnological (recombinant insulin, monoclonal antibodies).

Pharmacokinetics: What the Body Does to the Drug

Four processes, in order — ADME .

Absorption

Movement from the site of administration into the systemic circulation. Intravenous administration bypasses absorption entirely and is therefore 100% bioavailable and fastest.

Factors that change absorption:

Route — see Section 18.3 for the onset ordering

Perfusion at the site — this is the single most important prehospital factor. A shocked, vasoconstricted patient absorbs subcutaneous and intramuscular drugs slowly and unpredictably, which is why the intravenous or intraosseous route is preferred in shock, and why the well-perfused vastus lateralis is chosen for intramuscular epinephrine in anaphylaxis

  • Lipid solubility and molecular size
  • Gastric contents, pH, and motility for oral drugs

First-pass metabolism — oral drugs are absorbed into the portal circulation and pass through the liver before reaching the systemic circulation, where a large fraction may be inactivated. Sublingual, buccal, rectal, inhaled, and parenteral routes bypass first pass , which is why sublingual nitroglycerin works and swallowed nitroglycerin does not

Distribution

Movement from blood into tissue, determined by perfusion, protein binding, and barriers.

Protein binding: only the unbound (free) fraction is active. Hypoalbuminaemia — malnutrition, liver disease, critical illness — raises the free fraction and the effect of a standard dose. Competition for binding sites is a major interaction mechanism.

Barriers: the blood-brain barrier admits lipid-soluble drugs; the placenta admits most drugs, so any drug given to a pregnant patient should be assumed to reach the fetus .

Volume of distribution explains why water-soluble drugs are dosed on lean body weight and lipid-soluble drugs distribute extensively into adipose tissue.

Metabolism (Biotransformation)

Predominantly hepatic, mostly via the cytochrome P450 enzyme system. Metabolism usually inactivates a drug, but sometimes activates a prodrug .

Enzyme inducers (carbamazepine, rifampin, chronic alcohol) speed metabolism and reduce drug effect.

Enzyme inhibitors (many antifungals, macrolide antibiotics, grapefruit juice) slow metabolism and increase drug effect, sometimes to toxicity.

Liver disease reduces metabolism — standard doses of sedatives, opioids, and benzodiazepines behave as relative overdoses.

Excretion

Mostly renal, with biliary, pulmonary (volatile agents), and minor routes in sweat, saliva, and breast milk. Renal impairment causes accumulation of renally cleared drugs, and the older adult has reduced clearance even with a normal creatinine.

Half-life is the time for the plasma concentration to fall by half; roughly four to five half-lives are needed to eliminate a drug, and the same to reach steady state on repeated dosing. This is the concept behind renarcotization : naloxone has a half-life of roughly 30 to 90 minutes while many opioids last far longer, so the patient can re-sedate after naloxone wears off.

Pharmacodynamics: What the Drug Does to the Body

Most drugs act on receptors :

  • Term Meaning Example
  • Agonist Binds and activates the receptor Epinephrine at alpha and beta receptors
  • Antagonist Binds and blocks, producing no effect itself Naloxone at opioid receptors
  • Partial agonist Binds and produces a submaximal effect Buprenorphine at opioid receptors
  • Competitive antagonist Blockade can be overcome by more agonist Naloxone
  • Non-competitive antagonist Blockade cannot be overcome by more agonist Aspirin's irreversible COX-1 inhibition

Other core concepts: potency (dose required for an effect) is not the same as efficacy (the maximal effect achievable); the therapeutic index is the margin between an effective and a toxic dose, and drugs with a narrow index — digoxin, lithium, warfarin, phenytoin, theophylline — are the ones that cause prehospital toxicity; tolerance requires increasing doses for the same effect; tachyphylaxis is rapid tolerance after repeated doses over a short interval, as seen with repeated salbutamol.

Interactions

CPCF #5 names three interaction types explicitly:

Drug–drug: nitroglycerin with a PDE-5 inhibitor (catastrophic hypotension); an opioid with a benzodiazepine (respiratory depression); an anticoagulant with an antiplatelet (bleeding); a beta blocker blunting the response to epinephrine in anaphylaxis.

Drug–food: grapefruit juice inhibiting cytochrome P450; vitamin K-rich foods opposing warfarin; tyramine-containing foods with monoamine oxidase inhibitors.

Drug–condition: a beta blocker in asthma (bronchospasm); an NSAID in renal impairment or gastrointestinal bleeding; ASA in a child with a viral illness (Reye syndrome).

Interactions can be additive , synergistic (greater than additive — the opioid and benzodiazepine combination), or antagonistic .

Adverse Effects and the Special Populations

Side effect: a predictable, dose-related, non-therapeutic effect — salbutamol causing tremor and tachycardia.

Adverse drug reaction: a harmful, unintended response at normal doses.

Allergic reaction: immune-mediated, and not dose-related. Distinguish it from intolerance. A patient who reports that morphine makes them nauseated has an intolerance, not an allergy, and recording it as an allergy may deny them appropriate analgesia for life.

Idiosyncratic reaction: unexpected and unpredictable.

Iatrogenic: caused by the treatment itself.

Special populations: neonates and infants have immature hepatic and renal clearance; children are dosed by weight , with a maximum that must not exceed the adult dose; older adults have reduced clearance, more drugs, and more interactions (Section 16.2); pregnancy alters volume of distribution and protein binding, and every drug should be assumed to cross the placenta; renal and hepatic impairment both cause accumulation.

Important

Polypharmacy is a clinical finding, not background information. A medication list is a compressed medical history and a risk assessment. Beta blockers explain an absent tachycardia in shock; anticoagulants convert a minor fall into a major head injury; diuretics and ACE inhibitors explain electrolyte disturbance; anticholinergics explain hyperthermia and confusion. Read the list, and read what is missing from it — the insulin that has run out, the diuretic that was stopped last week.